Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

10.76 -0.08 (-0.74%)

Streaming Delayed Price Updated: 9:49 AM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035

December 03, 2025

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...

Via MarketMinute

Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know

November 21, 2025

A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Via StockStory

Topics Economy

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

November 14, 2025

Via Benzinga

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS)

November 12, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

What's going on in today's session: S&P500 gap up and gap down stocks ↗

November 12, 2025

Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

3 Unprofitable Stocks That Concern Us

November 11, 2025

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital...

Via StockStory

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

Exploring the top movers within the S&P500 index during today's session. ↗

November 11, 2025

Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.

Via Chartmill

Wall Street Pauses, Silver Reclaims $50 With Shutdown End In Sight: What's Moving Markets Tuesday? ↗

November 11, 2025

U.S. equities took a breather on Tuesday, stabilizing after Monday's sharp rally as investors awaited a House vote on the temporary spending bill expected to end the record-long government shutdown...

Via Benzinga

What's going on in today's session: S&P500 movers ↗

November 11, 2025

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.

Via Chartmill

Viatris (VTRS) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Viatris (VTRS) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

VIATRIS INC (NASDAQ:VTRS) Q3 2025 Earnings Beat Expectations ↗

November 06, 2025

Viatris beats Q3 2025 earnings estimates with strong EPS of $0.67, showcasing solid profitability and operational execution.

Via Chartmill

Topics Earnings

Viatris’s (NASDAQ:VTRS) Q3 Sales Top Estimates

November 06, 2025

Medication company Viatris (NASDAQ:VTRS) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $3.76 billion. The company’s full-year revenue guidance of $14.1...

Via StockStory

Viatris (VTRS) Q3 Earnings Report Preview: What To Look For

November 04, 2025

Medication company Viatris (NASDAQ:VTRS) will be reporting earnings this Thursday before market open. Here’s what investors should know.

Via StockStory

Topics Artificial Intelligence

3 Stocks Under $50 We’re Skeptical Of

November 02, 2025

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...

Via StockStory

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 30, 2025

Via Benzinga

1 S&P 500 Stock to Target This Week and 2 We Brush Off

October 29, 2025

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,...

Via StockStory

Topics Stocks

What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter ↗

October 24, 2025

What Occidental Petroleum’s Latest Backer Sees in Oil’s Next Chapter

Via The Motley Fool

Topics Energy Regulatory Compliance

3 Volatile Stocks with Warning Signs

October 24, 2025

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...

Via StockStory

Topics Artificial Intelligence

3 Reasons to Sell VTRS and 1 Stock to Buy Instead

October 22, 2025

Viatris’s 35.8% return over the past six months has outpaced the S&P 500 by 8.4%, and its stock price has climbed to $10.44 per share. This was partly due to its solid quarterly results, and the run-up...

Via StockStory

Topics Government Stocks World Trade

QSM Asset Management Takes $11.5 Million Stake in Rio Tinto, Expands Energy Exposure ↗

October 16, 2025

Via The Motley Fool

QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market ↗

October 16, 2025

Via The Motley Fool

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs ↗

October 09, 2025

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns.

Via Benzinga

Topics Government World Trade

3 Cash-Producing Stocks We Keep Off Our Radar

October 01, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

3 Mid-Cap Stocks We Keep Off Our Radar

September 16, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

Explore the top gainers and losers within the S&P500 index in today's session. ↗

September 15, 2025

Let's delve into the developments on the US markets one hour before the close of the markets on Monday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.

Via Chartmill

3 Value Stocks We Steer Clear Of

September 09, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

1 Unprofitable Stock with Impressive Fundamentals and 2 That Underwhelm

September 08, 2025

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

1 Volatile Stock on Our Buy List and 2 Facing Challenges

September 04, 2025

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.